Case Study RPN

In order to develop a complete and successful access plan, RPN proposes specific strategic approaches that accelerate the accessibility of the therapeutic solution to meet patient clinical needs.
The initial approach generally involves the analysis of current therapeutic algorithm in which the product should be positioned and analysis of strengths/hurdles. In parallel, data can be shared and discussed with KOLs and Payers to support the definition of strategy, clarify the precise place in therapy of the new technology and the specific unmet need recognized at national level.
After defining these first aspects, RPN can develop, in advance to many countries, an effective EAP (early access program) that allows rapid availability of the new drug for the benefit of patients.

At the same time, in the pre-P&R submission phase, RPN can support with the development of HE Models which identify and highlights the economic/social impact that the new therapeutic solution can have on the Italian environment.
On the basis of the strategic analysis performed and the wide experience in the field, RPN can support with the preparation of the Pricing & Reimbursement Dossier and the Innovation application. After the submission to AIFA, RPN supports clients with close follow-up and attendance of meetings with AIFA Commissions up to the publication of the P&R decree in the Italian Official Journal.

Finally, RPN can support and coordinate the client’s regional activities in such a way as to accelerate and optimize the timing of regional access in the Italian Local Health Units.

Further Cases